Pantocalcin (Hopantenic acid) is commonly used to help with symptoms related to functional stress across several key areas of nervous system function, particularly in situations where cognitive and behavioral instability may be present. Its use is considered relevant in contexts involving a wide spectrum of neurological and developmental disorders.

The medication is relevant for managing symptom clusters related to impaired attention, diminished memory capacity, and difficulties in learning processes. It is also applied in addressing hyperactivity, impulsivity, tic disorders, and asthenic syndrome (mental fatigue). The overall benefit supports the patient during difficult episodes by helping maintain a sense of stability when symptoms are more noticeable. The medication is commonly used for managing conditions characterized by periods of heightened symptoms, including Attention Deficit Hyperactivity Disorder (ADHD), various forms of cognitive impairment, developmental delays (such as delayed speech), tic disorders, and asthenic states. It is also applied in clinical settings for supportive symptom management alongside other necessary psychiatric treatments.

---

Quick Fact: Relief for Asthenic and Cognitive Strain
The medication is commonly used during phases of increased distress or high intellectual load to support patients experiencing pervasive mental fatigue and to assist with supporting general well-being during symptomatic phases.

Eligibility Map: Who Can and Cannot Use Pantocalcin — Official Regulatory Information

The eligibility profile for Pantocalcin (Hopantenic acid) is defined by official regulatory documentation, which specifies both the allowed populations and those who are formally contraindicated.

---

Populations with Established Use

Use is established across the full age spectrum. The medicine is documented for use in the Pediatric Population (starting from 6 months of age), Adults, and the Geriatric Population.

Absolute Contraindications

Regulatory documents stipulate that Pantocalcin must not be used by the following groups or under the following conditions:

• I trimester of Pregnancy and during Lactation (Breastfeeding).
• Hypersensitivity to hopantenic acid or any component of the formulation.
• Acute Severe Renal Impairment (Acute Severe Kidney Diseases).
• Patients with Expressed Changes in Peripheral Blood Counts.

---

Eligibility Summary

While the drug's official profile confirms broad age-group eligibility, its use is strictly excluded where specific organ function or physiological states are present. These contraindications represent clear, label-based restrictions on who is legally ineligible to use the medicine.

The official regulatory documentation for Pantocalcin (Hopantenic acid) defines its interaction profile through documented pharmacodynamic outcomes rather than specific metabolic mechanisms like CYP enzyme involvement. The product is stated to engage in interactions that modify the effect of other centrally acting medications.

Documented Interaction Outcomes

Hopantenic acid is formally documented to prolong the action of medicines in the Barbiturate class and to enhance the action of various Anticonvulsants (anti-seizure medicines). A further stated interaction is the potentiation of Local Anesthetics, such as Procaine.

---

Protective and Enhancing Interactions

A distinct finding in the official labeling is a protective interaction, where the medicine is stated to prevent the side effects associated with specific psychotropic agents, including Neuroleptics, Phenobarbital, and Carbamazepine. The effect of Hopantenic acid is also documented as being enhanced when combined with the substances Glycine and Etidronic Acid.

---

Usage Restriction

The regulatory profile includes a constraint on co-administration: simultaneous use with other nootropic and stimulating agents of the central nervous system is not recommended when the drug is administered under conditions of long-term treatment. No specific timing separation requirements or formal drug-drug contraindications are listed in the official interaction section.

Пантокальцин (calcium hopantenate) functions as a structural derivative of gamma-aminobutyric acid (GABA). The active component, after crossing the blood-brain barrier, primarily influences the GABAergic system, the central inhibitory neurotransmitter pathway. Specifically, calcium hopantenate interacts with GABAB receptors, acting as a ligand to modulate their activity. This interaction contributes to the stabilization of the excitability threshold of neuronal membranes.

The compound’s influence on the GABAergic pathway shifts the balance between excitatory and inhibitory neurotransmission in the central nervous system (CNS). Furthermore, the molecule affects the metabolic turnover of GABA itself by influencing the activity of enzymes involved in its synthesis and degradation.

This molecular cascade culminates in the optimization of cerebral metabolic processes. The compound modulates the utilization of glucose and oxygen by neuronal tissue, thereby influencing cellular energy production. The net system-level physiological consequence of this dual GABAergic and metabolic activity is the modulation of the overall functional state of the CNS.

How to Use Пантокальцин

Administration of Пантокальцин (Hopantenic acid) is strictly based on prescribing information, defining the route, dosing structure, and duration of use.

Official Usage Patterns

The medication is designed for oral administration and is available in two primary forms: tablets (250 mg and 500 mg) and an oral solution (150 mg/ml). The tablets are scored, allowing for division into smaller doses as required by the prescribed regimen.

Dosing Frequency and Timing

The total amount for the day is generally administered in divided doses, typically 2 to 4 times per day. A key procedural instruction is the timing of intake: the medicine must be taken 15 to 30 minutes after consuming a meal. Furthermore, administration is recommended during the morning and daytime hours to align with the drug’s pharmacological properties.

Official Dosing Ranges and Course Duration

Official dosing is structured by age and condition:

Population	Typical Daily Dose Range (Adults)	Typical Daily Dose Range (Pediatrics)
Standard Use	1500 mg to 3000 mg	750 mg to 3000 mg

The duration of use is defined in specific courses. A standard course of treatment typically lasts from one to four months, though it may be extended up to six months in certain clinical contexts. Following the completion of a course, a mandatory waiting interval of 3 to 6 months is required before beginning any subsequent course.

Population and Form Restrictions

For administration to children, the tablet form is unsuitable for those under 3 years of age, requiring the use of the oral solution. Tablet administration to children aged 3 to 5 years must be performed under adult supervision. No dose adjustments are explicitly required for the elderly or for patients with liver insufficiency.

Пантокальцин: Recent Clinical Evidence

This overview describes the types of research that have been conducted on hopantenic acid and the current landscape of available evidence, focusing on what was studied and what remains uncertain.

---

Studies Exploring Cognitive Impairment and Developmental Delays

Hopantenic acid was studied in research exploring how symptoms change over time in clinical situations related to cognitive challenges and developmental delays. Randomized Controlled Trials (RCTs) and other controlled clinical studies were used in research examining these conditions. The research focused on specific, vulnerable pediatric cohorts, such as infants experiencing psychomotor developmental delays or children with cerebral palsy.

The studies monitored developmental measures and examined specific neurocognitive outcomes. In these cohorts, studies reported measured shifts in these developmental and cognitive scores during the observation period. However, the follow-up durations were limited, typically lasting only a couple of months, meaning long-term effects are not fully established. The results apply only to the populations studied.

---

Studies Exploring Attention Deficit Hyperactivity Disorder (ADHD) and Related Symptoms

Hopantenic acid was evaluated in studies examining outcomes related to ADHD symptoms. The evidence base includes placebo-controlled trials and observational research, applied in studies examining patient-reported experiences and structured symptom measurements. Researchers monitored changes in core ADHD symptom severity and explored broader outcomes reflecting daily functioning.

Research highlights changes measured during the study period, particularly when patients was observed in studies over defined time intervals extending up to six or eight months. Data for certain groups, particularly adult populations, remain insufficient, and there is limited information for long-term outcomes that track effects beyond the intermediate term.

---

Study Populations and Research Gaps

Research was evaluated in specific patient groups where functional limitations were present, including very young children and those with pre-existing conditions. Despite this specific focus, comparative evidence is lacking for many broader groups. The primary research gap is the scarcity of large-scale, published, high-quality Randomized Controlled Trials that provide high certainty across all studied indications.

Common questions about Пантокальцин (FAQ)

---

Q: What are the official contraindications (who should not take it)?

Official regulatory documents define several conditions where the medicine is formally contraindicated (should not be used). These include the first trimester of pregnancy, during lactation (breastfeeding), in cases of known hypersensitivity to the active substance, and for patients with acute severe renal impairment or expressed changes in peripheral blood counts. Additionally, the tablet form is specifically contraindicated for administration to children under 3 years old.

---

Q: Is Pantocalcin safe during pregnancy, and what about breastfeeding?

Official product information states that this medicine is contraindicated, meaning it must not be used, during the first trimester of pregnancy and throughout the entire period of lactation (breastfeeding). The product label does not provide specific safety information regarding use during the second or third trimesters of pregnancy.

---

Q: What is the duration of treatment, and how long of a break is needed?

A standard course of treatment typically lasts from one to four months, though regulatory information notes that it may be extended up to six months. Following the completion of a course, a mandatory waiting interval of 3 to 6 months is required before beginning any subsequent course of treatment. The specific length of a course and the required break interval are matters for clinical decision-making.

---

Q: What is the mechanism of action of Pantocalcin?

According to official regulatory sources, the active substance, hopantenic acid, influences the brain's main inhibitory signaling system, known as the GABAergic system, primarily by interacting with GABAB receptors. This activity helps to stabilize the excitability threshold of nerve cells. Official documentation notes that it also modulates cerebral metabolic processes, including the utilization of glucose and oxygen by neuronal tissue.

How to Store and Dispose of Пантокальцин (Pantocalcin)

Official regulatory guidelines strictly define the conditions necessary for the storage and disposal of this medicine.

Storage Requirements

• Temperature: Store the product at a temperature that does not exceed 25°C (77°F).
• Light Protection: The medicine must be kept in a location that is protected from light.
• Child Safety: Пантокальцин must be kept out of the reach and sight of children.
• Shelf Life: The product must not be used after the expiration date, which for the tablet form is 4 years from manufacture.

Disposal Instructions

Disposal must follow specific pharmaceutical waste procedures to protect the environment. It is prohibited to throw the medicine away into the sewerage system (wastewater). Unused or expired Пантокальцин should be disposed of by consulting a pharmacist for the proper destruction method.